Full Press Release Details
IDEAYA Receives Authorization to Proceed with Phase 1 2 Tissue Type Agnostic Basket Trial to Treat Patients with Tumors Harboring GNAQ 11 Mutations and PKC Fusions.
IDYA
IDEAYA Receives Authorization to Proceed with Phase 1 2 Tissue Type Agnostic Basket Trial to Treat Patients with Tumors Harboring GNAQ 11 Mutations and PKC Fusions
Key Takeaway: IDEAYA Receives Authorization to Proceed with Phase 1 2 Tissue Type Agnostic Basket Trial to Treat Patients with Tumors Harboring GNAQ 11 Mutations and PKC Fusions
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+47%
120-day peak, hindsight
Typical move
5.2%
average across 6 past catalysts
Cash runway
~42 mo
Minimal dilution risk
Lead asset
IDE892
Phase 1 · NSCLC Adenocarcinoma